NOTE 20. NET LOSS PER SHARE

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the years ended December 31 (in thousands):



	2016			2015			2014
Numerator:
(Loss) income from continuing operations	$	(3,223,772	)	$	(300,399	)	$	61,608
Less: Net income (loss) from continuing operations attributable to noncontrolling interests	16			(283		)	(399		)
(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders	$	(3,223,788	)	$	(300,116	)	62,007
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax	(123,278		)	(1,194,926		)	(783,326		)
Net loss attributable to Endo International plc ordinary shareholders	$	(3,347,066	)	$	(1,495,042	)	$	(721,319	)
Denominator:
For basic per share data—weighted average shares	222,651			197,100			146,896
Dilutive effect of ordinary share equivalents	—			—			2,600
Dilutive effect of various convertible notes and warrants	—			—			7,234
For diluted per share data—weighted average shares	222,651			197,100			156,730

Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period. Ordinary share equivalents are measured under the treasury stock method.

All stock options and stock awards were excluded from the diluted share calculation for the years ended December 31, 2016 and 2015 because their effect would have been anti-dilutive, as the Company was in a loss position. For the year ended December 31, 2014, stock options and stock awards of 0.7 million were excluded from the diluted share calculation because their effect would have been anti-dilutive.

The 1.75% Convertible Senior Subordinated Notes due April 15, 2015 were only included in the dilutive net loss per share calculations using the treasury stock method during periods in which the average market price of our ordinary shares was above the applicable conversion price of the Convertible Notes, or $29.20 per share, and the impact would not have been anti-dilutive. In these periods, under the treasury stock method, we calculated the number of shares issuable under the terms of these notes based on the average market price of the shares during the period, and included that number in the total diluted shares outstanding for the period.

We entered into convertible note hedge and warrant agreements, which have subsequently been settled, that, in combination, had the economic effect of reducing the dilutive impact of the Convertible Notes. However, we separately analyzed the impact of the convertible note hedge and the warrant agreements on diluted weighted average shares outstanding. As a result, the purchases of the convertible note hedges were excluded because their impact would have been anti-dilutive. The treasury stock method was applied when the warrants were in-the-money with the proceeds from the exercise of the warrant used to repurchase shares based on the average share price in the calculation of diluted weighted average shares. Until the warrants were in-the-money, they had no impact to the diluted weighted average share calculation.

The dilutive impact of the 1.50% convertible senior notes due 2018 was calculated using the if-converted method, assuming the notes were converted at the time of issuance.